Promising treatment in current cancer trial
Positive preliminary results of a trial of regorafenib for
advanced oesophagogastric cancer have been presented at the
Gastrointestinal Cancers Symposium in San Francisco.
The trial, INTEGRATE, is being led by the investigator group,
Australasian Gastro-Intestinal Trials Group (AGITG), together with
colleagues from Korea and Canada and the CTC.
The major outcomes of the trial will be announced in the coming
In Australia, there are around 3,400 new cases
a year of cancers at the junction between the oesophagus and the
stomach. Around 2,400 people a year die from these cancers. New
treatment options are urgently needed because when surgery and
chemotherapy fail, no other proven effective treatments are
The study recruited 152 patients across 54
centres in four countries, to test the potential of regorafenib as
a possible treatment.
Said trial chair, Associate Professor Nick
Pavlakis (pictured): 'Our ability to co-ordinate the large number
of centres is a tribute to the capacity of this Australian trials
'Trials like this are critically important in
finding better treatments for GI cancers. They're the only way we
can establish whether a treatment is effective and safe or
He said clinical trials offer many benefits for
participants: 'Patients on trials are looked after very well, and
research has also shown they have higher survival rates.
'There's also an altruistic value, where
participants are actively helping to improve treatments for future
View the abstract here
For more information: integrate
16 January 2015